Lexarias DehydraTECH-CBD Hypertension Study HYPER-H21-4 Dosing Complete with No Serious Adverse Events

July 27, 2022

Consumer Packaged Goods

Lexaria Announces $3.6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

February 15, 2024
Better Choice Acquires Aimia Pet Healthco to Enter the GLP1 Pet Market

February 9, 2024
Inomin Expands Beaver-Lynx Critical Minerals Project

January 19, 2024
Lexaria Unveils Extensive Planned 2024 GLP-1 Study Program

January 16, 2024